Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROLINGUAL vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is converted to nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP levels in vascular smooth muscle. This leads to dephosphorylation of myosin light chains, causing vasodilation. It predominantly dilates venous capacitance vessels, reducing preload, and to a lesser extent dilates arterioles, reducing afterload.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Acute relief of an angina pectoris attack,Prophylaxis of angina pectoris before activities that may provoke an attack (off-label)
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
1 to 2 sprays (0.4 mg/spray) sublingually at onset of angina, may repeat every 5 minutes up to 3 doses; prophylactic use: 1 spray 5-10 minutes before activity.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
2-3 minutes for sublingual nitroglycerin; rapid decline due to extensive first-pass metabolism and high clearance (30-40 L/min). Clinical context: extremely short half-life necessitates continuous or frequent dosing for sustained effect.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Nitroglycerin is extensively metabolized in the liver by glutathione-S-transferases and in vascular smooth muscle by mitochondrial aldehyde dehydrogenase (ALDH2), producing dinitrate metabolites (1,2- and 1,3-glyceryl dinitrate) and mononitrates.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Renal (primarily as glucuronide conjugates and denitrated metabolites): ~60-80%; Fecal: ~20-40%; Biliary: negligible. Less than 1% excreted unchanged.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
~60% bound, primarily to albumin; low affinity, allowing rapid equilibration with tissues.
Isosorbide mononitrate is less than 5% bound to plasma proteins.
~3 L/kg (0.1-0.2 L/kg for parent drug; larger due to extensive tissue distribution including vascular smooth muscle). High Vd reflects extensive uptake into vessel walls and other tissues.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Sublingual: ~40-60% (avoiding first-pass hepatic metabolism); Oral: <1% (extensive presystemic clearance by hepatic glutathione-organic nitrate reductase).
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No dose adjustment required for any GFR level.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Child-Pugh A: no adjustment; Child-Pugh B: consider dose reduction (e.g., 1 spray); Child-Pugh C: avoid use or use extreme caution with reduced dose.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Not established in pediatric patients for sublingual spray; avoid use in children.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Start with lower dose (1 spray) due to increased sensitivity and risk of hypotension.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
Do not use NITROLINGUAL with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) or soluble guanylyl cyclase (s GC) stimulators (e.g., riociguat), as severe hypotension, syncope, or myocardial ischemia can occur.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension: May cause severe hypotension, especially in volume-depleted patients or those with low systolic blood pressure.,Headache: Common and may be severe; tolerance may develop.,Tolerance: Continuous or frequent use may lead to tolerance, requiring nitrate-free intervals.,Abrupt withdrawal: May precipitate angina; taper if discontinuing long-term therapy.,Hypertrophic cardiomyopathy: May worsen outflow obstruction.,Increased intracranial pressure: Use cautiously in patients with elevated intracranial pressure (e.g., cerebral hemorrhage).
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitroglycerin or any component of the formulation,Concurrent use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) or s GC stimulators (riociguat),Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Constrictive pericarditis, cardiac tamponade, restrictive cardiomyopathy,Acute myocardial infarction with low filling pressure (e.g., right ventricular infarction)
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
No specific food interactions. Avoid alcohol, which can exacerbate hypotension. Maintain adequate hydration.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin caused decreased fetal weight and increased fetal resorptions at doses 50 times the human dose. Risk cannot be ruled out; use only if clearly needed. No known teratogenicity in first trimester, but caution in third trimester due to maternal hypotension risk.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Nitroglycerin is excreted in human milk in small amounts. M/P ratio unknown. No adverse effects reported in breastfeeding infants. Caution when administered to nursing women.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
No specific dose adjustment recommended for pregnancy. Use lowest effective dose due to increased plasma volume and clearance. Monitor for hypotension, which may be more pronounced in pregnancy. Titrate based on clinical response.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
NITROLINGUAL (nitroglycerin sublingual spray) is first-line for acute angina. Administer 1-2 sprays at onset of chest pain; may repeat every 5 minutes up to 3 doses. Avoid in patients with severe hypotension (SBP <90 mm Hg), right ventricular infarction, or concomitant use of phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) within 24-48 hours. Monitor for orthostatic hypotension; patient should sit or lie down during administration. The spray is absorbed via oral mucosa; do not inhale or swallow. Onset: 1-3 minutes; duration: 30-60 minutes. Do not shake canister; prime before first use or if not used for >6 weeks.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Use 1-2 sprays under or on the tongue at first sign of chest pain.,Do not shake the canister; hold it upright and spray onto or under the tongue.,Avoid swallowing or inhaling the spray; let it absorb through the oral mucosa.,Wait 5 minutes after the first dose; if chest pain persists, repeat up to 3 doses total.,If pain is not relieved after 3 doses, seek emergency medical help immediately.,Do not take with erectile dysfunction medications (e.g., sildenafil, tadalafil) within 24-48 hours.,Sit or lie down when using the spray to prevent dizziness or fainting.,Store at room temperature away from heat; do not freeze. Check expiration date.,Prime the spray before first use (spray 5 times into air) or if not used for 6 weeks (spray once).,Common side effects: headache, dizziness, flushing, low blood pressure.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROLINGUAL vs MONOKET, answered by our medical review team.
NITROLINGUAL is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP levels in vascular smooth muscle. This leads to dephosphorylation of myosin light chains, causing vasodilation. It predominantly dilates venous capacitance vessels, reducing preload, and to a lesser extent dilates arterioles, reducing afterload.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROLINGUAL and MONOKET depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROLINGUAL is: 1 to 2 sprays (0.4 mg/spray) sublingually at onset of angina, may repeat every 5 minutes up to 3 doses; prophylactic use: 1 spray 5-10 minutes before activity.. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROLINGUAL and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROLINGUAL is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin caused decreased fetal weight and increased fetal resorptions at doses 50 times th. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.